NDAORALCAPSULEPriority Review
Approved
Feb 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
Priority Review
POMALYST (pomalidomide) by Bristol Myers Squibb is immunomodulatory, antiangiogenic, and antineoplastic properties. Approved for multiple myeloma. First approved in 2013.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POMALYST (pomalidomide) is an oral immunomodulatory thalidomide analog approved by the FDA in February 2013 for the treatment of multiple myeloma. The drug works through cereblon-mediated degradation of Aiolos and Ikaros proteins, triggering direct cytotoxic effects and enhancing T-cell and NK-cell immunity while suppressing pro-inflammatory cytokines. Pomalidomide demonstrates efficacy in lenalidomide-resistant disease and synergizes with dexamethasone, positioning it as a key salvage therapy in the multiple myeloma treatment armamentarium.
$1.7BPart D
5.6 years to LOEMechanism of Action
immunomodulatory, antiangiogenic, and antineoplastic properties. Cellular activities of pomalidomide are mediated through its target cereblon, a component of a cullin ring E3 ubiquitin ligase enzyme complex. In vitro, in the presence of drug, substrate proteins (including Aiolos and Ikaros) are…
Pharmacologic Class:
Thalidomide Analog
Indications (1)
Worked on POMALYST at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.